Country: Awstralja
Lingwa: Ingliż
Sors: Department of Health (Therapeutic Goods Administration)
abacavir sulfate, Quantity: 702 mg (Equivalent: abacavir, Qty 600 mg); lamivudine, Quantity: 300 mg; dolutegravir, Quantity: 50 mg
ViiV Healthcare Pty Ltd
Abacavir sulfate,Dolutegravir,Lamivudine
Tablet, film coated
Excipient Ingredients: microcrystalline cellulose; sodium starch glycollate; povidone; magnesium stearate; purified water; mannitol; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black
Oral
30 tablets
(S4) Prescription Only Medicine
TRELAVUE is indicated for the treatment of Human Immunodeficiency Virus (HIV) infection in adults and adolescents from 12 years of age who are antiretroviral treatment-na?ve or are infected with HIV without documented or clinically suspected resistance to any of the three antiretroviral agents (dolutegravir, abacavir or lamivudine) in TRELAVUE.
Visual Identification: Purple, biconvex, film coated oval tablets (approximately 22 x 11 mm), debossed with 572 Tri on one face.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 36 Months; Container Temperature: Store below 30 degrees Celsius; Container Closure: Child resistant closure
Registered
TRELAVUE 1 TRELAVUE FILM-COATED TABLETS _50 mg dolutegravir (as dolutegravir sodium) / 600 mg abacavir (as abacavir sulfate) / 300 mg lamivudine _ CONSUMER MEDICINE INFORMATION PATIENTS TAKING TRELAVUE, WHICH CONTAINS ABACAVIR, MAY DEVELOP A HYPERSENSITIVITY REACTION (SERIOUS ALLERGIC REACTION) WHICH CAN BE LIFE-THREATENING IF TREATMENT WITH TRELAVUE IS CONTINUED. CONTACT YOUR DOCTOR IMMEDIATELY FOR ADVICE ON WHETHER YOU SHOULD STOP TAKING TRELAVUE IF: 1) YOU GET A SKIN RASH OR 2) YOU GET ONE OR MORE SYMPTOMS FROM AT LEAST TWO OF THE FOLLOWING GROUPS: − FEVER − SHORTNESS OF BREATH, SORE THROAT OR COUGH − NAUSEA OR VOMITING OR DIARRHOEA OR ABDOMINAL PAIN − SEVERE TIREDNESS OR ACHINESS OR GENERALLY ILL FEELING IF YOU HAVE HAD A HYPERSENSITIVITY (ALLERGIC) REACTION TO TRELAVUE TABLETS, NEVER TAKE TRELAVUE, OR ANY OTHER MEDICINAL PRODUCT CONTAINING ABACAVIR (KIVEXA, TRIZIVIR & ZIAGEN) AGAIN AS YOU MAY DEVELOP A LIFE THREATENING REACTION WHICH CAN BE FATAL. THERE IS AN ALERT CARD INCLUDED IN THE TRELAVUE PACK, TO REMIND YOU AND MEDICAL STAFF ABOUT ABACAVIR HYPERSENSITIVITY. THIS CARD SHOULD BE REMOVED FROM THE PACK AND KEPT WITH YOU AT ALL TIMES. SEE MORE DETAILS UNDER BEFORE YOU TAKE TRELAVUE. WHAT IS IN THIS LEAFLET? Please read this leaflet carefully before you take TRELAVUE. This leaflet answers some common questions about TRELAVUE (dolutegravir/abacavir/lamivudine). It does not contain all of the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the expected benefits of you taking TRELAVUE against the risks this medicine could have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT IS TRELAVUE USED FOR? TRELAVUE contains three active ingredients that are used to treat HIV infection in adults and children over 12 years old: dolutegravir, abacavir, and lamivudine. Dolutegravir belongs to a gr Aqra d-dokument sħiħ